However, a recent study showed the plasmatic pattern of matrix metalloproteinases (MMPs), especially MMP-9 and MMP-2 and their physiological tissue inhibitors, which are markedly altered in patients with CIDP [30]. The gene discussed is MMP2; the disease is chronic inflammatory demyelinating polyradiculoneuropathy.